August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been successfully finished. The phase I clinical study of IMM2510 is being conducted by Fudan University Shanghai Cancer Center. The initial dosing of IMM2510 appeared to be smooth. IMM2510 is a new antibody-receptor recombinant protein (mAb-Trap) that blocks both PD-1/PD-L1 and VEGF/VEGFR signaling pathways, showing great therapeutic potential for a variety of advanced solid tumor indications.